Abstract
BACKGROUND: The human immunodeficiency virus (HIV) is a key factor responsible for the high rates of tuberculosis (TB) in sub-Saharan Africa. Treatment of TB with rifampicin (R, RMP) containing short-course regimens is highly effective in HIV-infected adults. We conducted a study to compare the efficacy and safety of intermittent ethambutol (E, EMB) with two RMP-containing regimens to treat pulmonary TB in HIV-infected patients. SETTING: National Tuberculosis Treatment Centre, Mulago Hospital, Kampala, Uganda. DESIGN: This was a prospective cohort compared to two non-randomised control groups. The study group and the two control arms were treated with 2 months of isoniazid (H), RMP, pyrazinamide (Z) and EMB followed by 6 E3H3 for the study group and 4HR or 6HR for controls. RESULTS: Between April 1993 and March 2000, 136 patients were enrolled in the 2EHRZ/E3H3 arm, 147 in the 2EHRZ/4HR arm and 266 in the 2EHRZ/6HR arm. The relapse rate was 18.2 per 100 person-years observation (PYO) for the study regimen compared to 9.7/100 PYO (P = 0.0063) and 4.8/100 PYO (P = 0.0001) in patients treated with 2 EHRZ/4HR or 2EHRZ/6HR, respectively. CONCLUSION: The 2EHRZ/6E3H3 regimen is safe and effective but has a significant risk of relapse.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 39-44 |
| Number of pages | 6 |
| Journal | International Journal of Tuberculosis and Lung Disease |
| Volume | 10 |
| Issue number | 1 |
| State | Published - Jan 2006 |
| Externally published | Yes |
Fingerprint
Keywords
- Ethambutol
- HIV/AIDS
- Rifampicin
- Treatment
- Tuberculosis
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Cite this
Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala. / Okwera, Alphonse; Johnson, J. L.; Luzze, H.; Nsubuga, P.; Kayanja, H.; Cohn, D. L.; Nunn, P.; Ellner, J. J.; Whalen, C. C.; Mugerwa, R. D.
In: International Journal of Tuberculosis and Lung Disease, Vol. 10, No. 1, 01.2006, p. 39-44.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala
AU - Okwera, Alphonse
AU - Johnson, J. L.
AU - Luzze, H.
AU - Nsubuga, P.
AU - Kayanja, H.
AU - Cohn, D. L.
AU - Nunn, P.
AU - Ellner, J. J.
AU - Whalen, C. C.
AU - Mugerwa, R. D.
PY - 2006/1
Y1 - 2006/1
N2 - BACKGROUND: The human immunodeficiency virus (HIV) is a key factor responsible for the high rates of tuberculosis (TB) in sub-Saharan Africa. Treatment of TB with rifampicin (R, RMP) containing short-course regimens is highly effective in HIV-infected adults. We conducted a study to compare the efficacy and safety of intermittent ethambutol (E, EMB) with two RMP-containing regimens to treat pulmonary TB in HIV-infected patients. SETTING: National Tuberculosis Treatment Centre, Mulago Hospital, Kampala, Uganda. DESIGN: This was a prospective cohort compared to two non-randomised control groups. The study group and the two control arms were treated with 2 months of isoniazid (H), RMP, pyrazinamide (Z) and EMB followed by 6 E3H3 for the study group and 4HR or 6HR for controls. RESULTS: Between April 1993 and March 2000, 136 patients were enrolled in the 2EHRZ/E3H3 arm, 147 in the 2EHRZ/4HR arm and 266 in the 2EHRZ/6HR arm. The relapse rate was 18.2 per 100 person-years observation (PYO) for the study regimen compared to 9.7/100 PYO (P = 0.0063) and 4.8/100 PYO (P = 0.0001) in patients treated with 2 EHRZ/4HR or 2EHRZ/6HR, respectively. CONCLUSION: The 2EHRZ/6E3H3 regimen is safe and effective but has a significant risk of relapse.
AB - BACKGROUND: The human immunodeficiency virus (HIV) is a key factor responsible for the high rates of tuberculosis (TB) in sub-Saharan Africa. Treatment of TB with rifampicin (R, RMP) containing short-course regimens is highly effective in HIV-infected adults. We conducted a study to compare the efficacy and safety of intermittent ethambutol (E, EMB) with two RMP-containing regimens to treat pulmonary TB in HIV-infected patients. SETTING: National Tuberculosis Treatment Centre, Mulago Hospital, Kampala, Uganda. DESIGN: This was a prospective cohort compared to two non-randomised control groups. The study group and the two control arms were treated with 2 months of isoniazid (H), RMP, pyrazinamide (Z) and EMB followed by 6 E3H3 for the study group and 4HR or 6HR for controls. RESULTS: Between April 1993 and March 2000, 136 patients were enrolled in the 2EHRZ/E3H3 arm, 147 in the 2EHRZ/4HR arm and 266 in the 2EHRZ/6HR arm. The relapse rate was 18.2 per 100 person-years observation (PYO) for the study regimen compared to 9.7/100 PYO (P = 0.0063) and 4.8/100 PYO (P = 0.0001) in patients treated with 2 EHRZ/4HR or 2EHRZ/6HR, respectively. CONCLUSION: The 2EHRZ/6E3H3 regimen is safe and effective but has a significant risk of relapse.
KW - Ethambutol
KW - HIV/AIDS
KW - Rifampicin
KW - Treatment
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=33144471064&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33144471064&partnerID=8YFLogxK
M3 - Article
C2 - 16466035
AN - SCOPUS:33144471064
VL - 10
SP - 39
EP - 44
JO - International Journal of Tuberculosis and Lung Disease
JF - International Journal of Tuberculosis and Lung Disease
SN - 1027-3719
IS - 1
ER -